Edwards Lifesciences Corp. is an American company that develops medical products for the treatment of heart valve diseases and haemodynamic monitoring. The company is particularly well known for its catheter-based heart valve replacement systems, which enable minimally invasive procedures and thus significantly reduce the burden on patients compared with open-heart surgery. The company is included in the fund because Edwards Lifesciences’ technologies can improve patient outcomes and shorten recovery times.